What To Know
- The study, which was conducted in the Company’s labs, was performed according to international standard practice for assessment of hemolysis in continuous flow blood pumps.
- The Company’s ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky, and costly mechanical ventilation systems that require medically induced coma.
Inspira Technologies OXY B.H.N. Ltd announced today that it has successfully completed a pump bench study as the company progresses closer towards the manufacturing phase.
Inspira Technologies is developing an early extracorporeal respiratory support system, the ART device, which functions as an “external lung”. The ART device is intended to allow patients to remain awake during treatment, while potentially preventing the use of highly invasive, risky and costly mechanical ventilation systems.
The pump is a key component of any extracorporeal oxygenation system. This component includes a motor and a pump head. It pumps the patient’s blood outside of the body through the extracorporeal oxygenation system, allowing the lungs to rest. The bench study is an important milestone in the selection of the ART device’s pump.
Inspira’s proprietary ART device pump was compared to other leading centrifugal pumps. All pumps are designed to minimize the amount of damage to blood (hemolysis) during operation. The study, which was conducted in the Company’s labs, was performed according to international standard practice for assessment of hemolysis in continuous flow blood pumps. In this study, the hemolysis of centrifugal pumps was investigated in vitro by comparing various scenarios of operation.
Dagi Ben-Noon, Inspira’s Chief Executive Officer, stated: “The pump is one of the core components of our ART device. The pump experiment represents an important milestone for us as it enables us to progress to manufacturing phase.”
Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed an early extracorporeal respiratory support system, the ART device, which it believes will elevate and stabilize patient oxygen saturation levels. The Company’s ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky, and costly mechanical ventilation systems that require medically induced coma. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).